Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

November 06, 2024

Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.

October 30, 2024

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

October 16, 2024

Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers

October 11, 2024

Francisco Hernandez-Ilizaliturri, MD, discusses factors that inform the selection of CAR T-cell therapies for patients with follicular lymphoma.

October 11, 2024

Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial; results newly reported in The Lancet Oncology.

October 01, 2024

September 24, 2024

Black patients and older adults are least likely to undergo this treatment for blood cancers and hematologic disorders.

August 30, 2024

Philip McCarthy, MD, discusses a study of neutrophil gene signatures within focal lesions that are linked to progression-free survival in multiple myeloma.

August 30, 2024

Third year in a row cancer center has been ranked on this listing, based on employee surveys.

August 26, 2024

Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.

August 23, 2024

A study demonstrates that adding a JAK2 inhibitor to standard immunosuppressive drugs does not improve prevention of acute graft-versus-host disease.

August 22, 2024

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

August 19, 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

August 14, 2024

A study led by experts at Roswell Park Comprehensive Cancer Center suggests that e-cigarette use may help some people quit using combustible cigarettes. 

August 06, 2024

Francisco Hernandez-Ilizaliturri, MD, discusses deciding between CAR T-cell therapies or approved bispecific antibodies for diffuse large B-cell lymphoma.

August 02, 2024

Eunice Wang, MD, discusses ongoing research with menin inhibitors in patients with acute leukemias, as presented at the 2024 EHA Congress.

July 22, 2024

Shipra Gandhi, MD, discusses considerations for continuing with a CDK4/6 inhibitor or switching therapies in HER2- negative advanced breast cancer.

July 22, 2024

The FDA has expanded the orphan drug designation for SurVaxM, a brain cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center.

July 20, 2024

Roswell Park Comprehensive Cancer Center has promoted 3 nurses to leadership roles and new leaders were named in Case Management and Patient Education.

July 17, 2024

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.